Parenteral Production Services
Product Description
WuXi STA
-
Country/Region:United States
-
On CPHI since:2015
-
Certificates:3
-
Employees:5000+
Company types
Primary activities
Categories
Specifications
WuXi STA
-
Country/Region:United States
-
On CPHI since:2015
-
Certificates:3
-
Employees:5000+
Company types
Primary activities
More Products from WuXi STA (15)
-
Product Packaging & Labeling Solutions
At WuXi STA, we understand the need for flexibility at the early stages of clinical testing and how aspects such as effective dose, stability and compliance requirements can change your needs abruptly. Our packaging team will work with you to collect the relevant data and test various packaging options as ... -
Product Oral Dose Drug Product Development & Manufacturing
WuXI STA's comprehensive drug product development platform for oral dosage forms offers our clients a complete line of solutions from pre-formulation development through to final product manufacture at commercial scale. Our capabilities include;
• Solid oral tablet/capsule (including liquid... -
Product Clinical Supply Services
WuXi STA's Clinical Supply Services provide you with full life cycle management from global comparator sourcing, labelling and packaging, storage and distribution, as well as return and destruction. Our industry-leading CMC project management is carried out in an integrated “teamwork” mode, which ensures a... -
Product F2CS - "Fast to Clinical Supply" Platform
Your innovative therapy is ready to reach a key milestone with the IND date quickly approaching. You need a reliable partner to formulate and manufacture your therapy to meet the IND filing requirements and the dose needs for phase I studies fast.
Every innovation is unique so your partner needs... -
Product F4CL - "Fast for Commercial Launch" Platform
When your CMC projects approach the final step to commercial approval, you need to consider how to be sure your drugs successfully reach your intended markets.
Regulatory agencies have different requirements and timing. Trust in the right partner so you don’t need to worry abou... -
Product IND Enabling Preformulation Package (IEPP)
WuXi STA's IND Enabling Pre-formulation Package (IEPP) is an integrated and end-to-end developability assessment service for new chemical entities (NCE's). Through this comprehensive service, you can efficiently identify challenges and tailored solutions earlier for higher project success rates and lower o... -
Product Small Molecule API Development & Manufacturing
WuXI's unrivaled API development platform provides our client with a robust platform to bring their drug to market. With a proven track record of success and trust in bringing life changing therapeutics to market, we are a go-to partner for clients looking for tailored and customized drug development and m... -
Product Bioavailability Enhancement & Advanced Delivery Technologies
Our bioavailability toolbox offers a customizable solution to your drug delivery challenges.
- Spray-Dried Dispersion (SDD)
- Hot Melt Extrusion (HME)
- Nano-suspensions & Lipid Nanoparticles
- Softgel & Liquid Filled Capsules
- Injectable Formulations\
-
Product Peptide CRDMO Platform
WuXi TIDES's Peptide platform includes a complete offering of services to bring your protein therapeutic to market faster while supporting a wide variety of conjugates including PPMO, Peptide-Antibody, Peptide-Linkers.
Services include but are not limited to: - Comprehensive Discovery Service... -
Product Oligonucleotide CRDMO Platform
WuXi TIDES has a robust and integrated Oligo API Platform, offering R&D and manufacturing services from preclinical to commercial scale and operating out of our US FDA inspected facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modalities inc... -
Product Highly Potent API (HPAPI), ADC Payload, and Payload-Linker Manufacturing
Our Jinshan and Changzhou sites are equipped with multiple R&D labs as well as a dedicated cGMP HP Kilo lab and plant for producing and manufacturing highly potent APIs (HPAPI's), antibody drug conjugates (ADC's), payloads, and payload-linkers. We currently offer drug product manufacturing at STA’... -
Product Analytical Development Services
Our comprehensive suite of analytical services help to supplement the development and manufacture of your product, ensuring high quality and consistency throughout the process.
Services include:
- Analytical method development and validation
- API and drug product release tes...
WuXi STA resources (9)
-
News New drug product service delivers expedited CTM
Biotech and pharma innovators are facing considerable challenges to find CDMO partners with capacity and capability to quickly develop and deliver high-quality CTM with flexible options+
-
Sponsored Content End game strategies to reach patients globally and swiftly
The journey for new therapies is long; wondering if a proven therapy will be produced and distributed efficiently to reach the intended markets as soon as possible should not be another burden
-
Video Case Study - Integrated CMC to IND in 10 Months
A Case Study of WuXi Speed and Service for a client. The project, which encompassed an integrated CMC approach to bring a molecule to IND phase was completed in 10 months -
News Hoth Therapeutics and WuXi strike API and drug product deal for cancer therapeutic
WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide -
Video WuXi STA IND Enabling Preformulation Package
WuXi STA's IND Enabling Preformulation Package (IEPP) is an integrated developability assessment service for new chemical entities (NCEs) to efficiently identify challenges and solutions earlier for higher success rates and lower overall costs. This video explains the package and process. -
News WuXi STA completes acquisition of its first European facility
The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms
-
Brochure F2CS: Fast to Clinical Supply
F2CS - fast to clinical supply service package delivers reliable clinical trial materials (CTM) fast with flexible options custom developed by highly experienced integrated teams equipped with advanced technologies, working in parallel to save time. -
Whitepaper IND Enabling Pre-formulation Package (IEPP)
WuXi STA's pre-formulation package IEPP (IND Enabling Pre-formulation Package) helps you select the best drug candidates at late discovery phase and develop the most suitable formulation for phase I in 8-12 weeks,
